Advertisement

Molecular and Cellular Biochemistry

, Volume 444, Issue 1–2, pp 187–196 | Cite as

Oxyphenbutazone promotes cytotoxicity in rats and Hep3B cellsvia suppression of PGE2 and deactivation of Wnt/β-catenin signaling pathway

  • Shakir Saleem
  • Ruqaiyah Khan
  • Muhammad Afzal
  • Imran Kazmi
Article

Abstract

Hepatocellular carcinoma (HCC) is the fifth leading cause of death and is generally typified by elevated liver enzyme biomarkers, antioxidants, and chronic inflammation of hepatocytes. Although currently available drugs have shown remarkable alleviation of the cancerous condition, but at the same time they present a more severe challenge of toxic effects due to chemotherapy. Therefore, in order to bring more patient-compliant therapy, we aimed to refurbish the use of a COX inhibitor, oxyphenbutazone (OPB), with low dose of methotrexate (MTX) to treat diethyl nitrosamine (DENA)-induced HCC in Wistar rats and in Hep3B cells. Hep3B cells were subjected to assays like in vitro cytotoxicity, DNA synthesis, and caspase activity. The combination index was also evaluated, succeeding the cytotoxicity assay, to analyze the possible synergism. For in vivo study, Wistar strain male rats were given single intraperitoneal dose of DENA (200 mg/kg) and were supplied with sodium phenobarbital (0.1% in tap water) for promoting tumorigenesis throughout the study. MTX (2.5 and 5.0 mg/kg/week, ip) and OPB (70 mg/kg/week, po in two divided doses) were administered to the treatment groups from 3rd week till the termination of study. Several biochemical parameters including biomarkers of liver function, antioxidant enzymes, and histopathological examination of liver cells were tested. Significant synergism was witnessed in the cytotoxicity assay when Hep3B cells received varied dose combination treatment of MTX (0.25, 0.5, or 1.0 µmol/L) and OPB (2.5, 5.0, or 7.5 µmol/L). MTX (0.5 and 1.0 µmol/L) in combination with OPB (5.0 or 7.5 µmol/L) inhibited the cell proliferation as BrdU incorporation was quite low in DNA synthesis analysis, as well as caspase-9/-3 cascade was activated which led to apoptosis of cancer cells. Co-treatment with MTX and OPB exerted potential anticancer activity in rats than either of the drugs alone. Administration of combination therapy harmonized the DENA-induced elevation of serum biochemical parameters, including but not limited to, α-fetoprotein (AFP), alanine- and aspartate-aminotransferase, alkaline phosphatase, vascular endothelial growth factor (VEGF), and antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT), and lipid per oxidation (LPO). All these results were optimally substantiated by histopathological examination. As evident COX-2 catalyzes the synthesis of PGE2, needed in the activation of Wnt/β-catenin pathway, which in turn is responsible for activating the transcriptional proteins required for higher degree of cell division and thence growth. Therefore, inhibition of COX-2 by our novel combination infers that even low doses of MTX can elucidate noticeable anticancer activity when paired with OPB.

Keywords

Methotrexate Oxyphenbutazone Human hepatocellular carcinoma Hep3B cells Drug synergism DNA synthesis Anticancer COX-2 VEGF Antioxidant enzymes 

Abbreviations

BrdU

Bromodeoxyuridine

DMEM

Dulbecco’s modified Eagle’s medium

FBS

Fetal bovine serum

HCC

Hepatocellular carcinoma

HEPES

Hydroxyethyl piperazineethanesulfonic acid

HRP

Horseradish peroxidase

MTX

Methotrexate

OPB

Oxyphenbutazone

SRB

Sulforhodamine B

Notes

Acknowledgements

Authors are thankful to the Department of Pharmacology, Siddhartha Institute of Pharmacy, Dehradun, Uttarakhand, India, for the approval of the Project (SIP/IAEC/PCOL/01/2016) and all the possible help provided in carrying out this research work.

Compliance with ethical standards

Conflict of interest

Authors have no conflict of interest.

References

  1. 1.
    Kundu N, Campbell P, Hampton B, Lin CY, Ma X, Ambulos N, Zhao XF, Goloubeva O, Holt D, Fulton AM (2012). Antimetastatic activity isolated from Colocasia esculenta (taro). Anticancer Drugs 23(2):200–211CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hu S, Sun W, Wei W, Wang D, Jin J, Wu J, Chen J, Wu H, Wang Q (2013) Involvement of the prostaglandin E receptor EP2 in paeoniflorin-induced human hepatoma cell apoptosis. Anticancer Drugs 24(2):140–149CrossRefPubMedGoogle Scholar
  3. 3.
    Biziota E, Briasoulis E, Mavroeidis L, Marselos M, Harris AL, Pappas P (2016) Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells. Anticancer Drugs 27(3):216–224CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Kim JY, Alam F, Chung SW, Park J, Jeon OC, Kim SY, Son WC, Byun Y (2014) Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. Anticancer Drugs 25(9):1061–1071CrossRefPubMedGoogle Scholar
  5. 5.
    Ismail B, Fagnere C, Limami Y, Ghezali L, Pouget C, Fidanzi C, Ouk C, Gueye R, Beneytout JL, Duroux JL, Diab-Assaf M, Leger DY, Liagre B (2015) 2′-Hydroxy-4-methylsulfonylchalcone enhances TRAIL-induced apoptosis in prostate cancer cells. Anticancer Drugs 26(1):74–84CrossRefPubMedGoogle Scholar
  6. 6.
    Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:12866–12872PubMedGoogle Scholar
  7. 7.
    Vane J (1994) Towards a better aspirin. Nature 367:215–216CrossRefPubMedGoogle Scholar
  8. 8.
    Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397–11403CrossRefPubMedGoogle Scholar
  9. 9.
    Cheng X, Zhou T, Li B, Li M, Li L, Li Z et al (2013) Methotrexate and 5-aminoimidazole-4-carboxamide riboside exert synergistic anticancer action against human breast cancer and hepatocellular carcinoma. Acta Pharmacol Sin 34:951–959CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K et al (1999) Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29:688–696CrossRefPubMedGoogle Scholar
  11. 11.
    Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG et al (2001) Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 7:1410–1418PubMedGoogle Scholar
  12. 12.
    Matthews NS, Peck KE, Taylor TS, Mealey KL (2001) Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys. Am J Vet Res 62(5):673–675CrossRefPubMedGoogle Scholar
  13. 13.
    Lima A, Seabra V, Bernardes M, Azevedo R, Sousa H, Medeiros R (2014) Role of key TYMS polymorphisms on methotrexate therapeutic outcome in Portuguese rheumatoid arthritis patients. PLoS ONE 9:e108165CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Neradil J, Pavlasova G, Veselska R (2012) New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells. Klin Onkol 25(2):2S87–2S92PubMedGoogle Scholar
  15. 15.
    Fan LL, Sun GP, Wei W, Wang ZG, Ge L, Fu WZ et al (2010) Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World J Gastroenterol 16:1473–1481CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Vichai V, Kirtikara K. Sulforhodamine B (2016) Colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112–1116CrossRefGoogle Scholar
  17. 17.
    Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55CrossRefPubMedGoogle Scholar
  18. 18.
    Mai K, Andres J, Bobbert T, Maser-Gluth C, Möhlig M, Bähr V, et al (2007) Rosiglitazone decreases 11betahydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue. Clin Endocrinol (Oxf) 67(3):419–425CrossRefGoogle Scholar
  19. 19.
    Yiang GT, Chen YH, Chou PL, Chang WJ, Wei CW, Yu YL (2013) The NS3 protease and helicase domains of Japanese encephalitis virus trigger cell death via caspase dependent and independent pathways. Mol Med Rep 7:826–830CrossRefPubMedGoogle Scholar
  20. 20.
    Yiang GT, Yu YL, Hu SC, Chen MH, Wang JJ, Wei CW (2008) PKC and MEK pathways inhibit caspase-9/-3-mediated cytotoxicity in differentiated cells. FEBS Lett 582:881–885CrossRefPubMedGoogle Scholar
  21. 21.
    Tessitore L, Tomasi C, Greco M, Sesca E, Laconi E, Maccioni O et al (1996) A subnecrogenic dose of diethylnitrosamine is able to initiate hepatocarcinogenesis in the rat when coupled with fasting/refeeding. Carcinogenesis 17(2):289–292CrossRefPubMedGoogle Scholar
  22. 22.
    Wang W, Xu GL, Jia WD, Wang ZH, Li JS, Ma JL et al (2009) Expression and correlation of hypoxia inducible factor-1α, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis. J Int Med Res 37:417–425CrossRefPubMedGoogle Scholar
  23. 23.
    Treon SP, Chabner BA (1996) Concepts in use of high-dose methotrexate therapy. Clin Chem 42:1322–1329PubMedGoogle Scholar
  24. 24.
    Kern MA, Schubert D, Sahi D, Schoneweiss MM, Moll I, Haugg AM et al (2002) Proapoptotic and anti-proliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 36(4):885–894CrossRefPubMedGoogle Scholar
  25. 25.
    Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–1157CrossRefPubMedGoogle Scholar
  26. 26.
    Oshima T, Cao X, Grande F, Yamada R, Garofalo A, Louie S et al (2009) Combination effects of SC144 and cytotoxic anticancer agents. Anticancer Drugs 20:312–320CrossRefPubMedGoogle Scholar
  27. 27.
    Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL et al (2009) Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136(6):1136–1147CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kaldis P, Pagano M (2009) Wnt signaling in mitosis. Dev Cell 17(6):749–750CrossRefPubMedGoogle Scholar
  29. 29.
    Shiota G, Okubo M, Noumi T, Noguchi N, Oyama K, Takano Y et al (1999) Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 46:407–412PubMedGoogle Scholar
  30. 30.
    Staszkiewicz J, Gimble J, Cain C, Dietrich M, Burk D, Kirk-Ballard H et al (2009). Flow cytometric and immunohistochemical detection of in vivo BrdU-labeled cells in mouse fat depots. Biochem Biophys Res Commun 378(3):539–544CrossRefPubMedGoogle Scholar
  31. 31.
    Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ et al (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99(3):403–413CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Martinek R (1969) Practical clinical enzymology. Am J Med Technol 31:162Google Scholar
  33. 33.
    Drotman RB, Lawhorn GT (1978) Serum enzymes are indicators of chemical induced liver damage. Drug Chem Toxicol 1:163–171CrossRefPubMedGoogle Scholar
  34. 34.
    Ploa GL, Hewitt WR (1989) Detection and evaluation of chemically induced liver injury. In: Wallace HA (ed) Principle and methods of toxicology. Raven Press, New York, p 399Google Scholar
  35. 35.
    Clawson GA (1989) Mechanism of carbon tetrachloride hepatotoxicity. Pathol Immunopathol Res 8:104–112CrossRefPubMedGoogle Scholar
  36. 36.
    Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM et al (2009) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27:446–452CrossRefPubMedGoogle Scholar
  37. 37.
    Kuzuya T, Asahina Y, Tsuchiya K, Tanaka K, Suzuki Y, Hoshioka T et al (2011) Early decrease in alpha-fetoprotein, but not des-gamma-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 81:251–258CrossRefPubMedGoogle Scholar
  38. 38.
    Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL (2010) Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 116:4590–4596CrossRefPubMedGoogle Scholar
  39. 39.
    Keam B, Oh DY, Lee SH, Kim DW, Im SA, Kim TY et al (2008) A Phase II study of 5-fluorouracil and cisplatin systemic chemotherapy for inoperable hepatocellular carcinoma with alpha fetoprotein as a predictive and prognostic marker. Mol Med Rep 1:415–422PubMedGoogle Scholar
  40. 40.
    Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135CrossRefPubMedGoogle Scholar
  41. 41.
    Yang ZF, Poon RTP (2008) Vascular changes in hepatocellular carcinoma. Anat Rec 291:721–734CrossRefGoogle Scholar
  42. 42.
    Tarnawski AS, Michael KJ (2003) Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. J Mol Med 81:627–636CrossRefPubMedGoogle Scholar
  43. 43.
    Esterbauer H, Chesseman KH (1990) Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxy-nonenal. Methods Enzymol 186:407–421CrossRefPubMedGoogle Scholar
  44. 44.
    Hietanen E, Ahotupa M, Bartsch H (1987) Lipid peroxidation and chemically induced cancer in rats fed lipid rich diet. In: Lapis K, Kcharst S (eds) Carcinogeensis and tumor progression. Akademiaikiado, Budapest, pp 9–16Google Scholar
  45. 45.
    Klaunig JE, Kamendulis LM (2004) The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44:239–267CrossRefPubMedGoogle Scholar
  46. 46.
    Heinrich P, Georg L, Petro E (2006) Biochemie und pathobiochemie. Springer, Berlin, p 399Google Scholar
  47. 47.
    Muller FL, Lustgarten MS, Jang Y, Richardson A, Van RH (2007) Trends in oxidative aging theories. Free Radic Biol Med 43:477–503CrossRefPubMedGoogle Scholar
  48. 48.
    Robak J, Glyglewsi RJ (1988) Flavonoids are scavengers of superoxide anions. Biochem Pharmacol 37:837–841CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Glocal School of PharmacyGlocal UniversitySaharanpurIndia
  2. 2.Department of Pharmacology, College of PharmacyAljouf UniversitySakakaKingdom of Saudi Arabia
  3. 3.Siddhartha Institute of PharmacyDehradunIndia

Personalised recommendations